Further evidence for overall benefit of MHC diversity and antigenic coverage are found in the analyses of determinants of positive immunotherapeutic cancer treatment outcomes: An increased MHC‐associated peptide diversity, and accompanied increased probability of presentation of neoantigens are a strong determinant of the outcome of immune checkpoint blockade in cancer [60, 61]. Here, HLA-C is linked to cancer.